These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 8123638

  • 21. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor.
    Stafforini DM, McIntyre TM, Carter ME, Prescott SM.
    J Biol Chem; 1987 Mar 25; 262(9):4215-22. PubMed ID: 3549727
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein.
    Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, Du BN, Fogelman AM, Berliner JA.
    J Clin Invest; 1995 Feb 25; 95(2):774-82. PubMed ID: 7860760
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles.
    Marathe GK, Zimmerman GA, McIntyre TM.
    J Biol Chem; 2003 Feb 07; 278(6):3937-47. PubMed ID: 12466264
    [Abstract] [Full Text] [Related]

  • 29. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease.
    Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD.
    Prostaglandins Leukot Essent Fatty Acids; 2006 Aug 07; 75(2):117-26. PubMed ID: 16843649
    [Abstract] [Full Text] [Related]

  • 30. Human plasma platelet-activating factor acetylhydrolase. Purification and properties.
    Stafforini DM, Prescott SM, McIntyre TM.
    J Biol Chem; 1987 Mar 25; 262(9):4223-30. PubMed ID: 3558407
    [Abstract] [Full Text] [Related]

  • 31. Role of lecithin-cholesterol acyltransferase in the metabolism of oxidized phospholipids in plasma: studies with platelet-activating factor-acetyl hydrolase-deficient plasma.
    Subramanian VS, Goyal J, Miwa M, Sugatami J, Akiyama M, Liu M, Subbaiah PV.
    Biochim Biophys Acta; 1999 Jul 09; 1439(1):95-109. PubMed ID: 10395969
    [Abstract] [Full Text] [Related]

  • 32. Platelet-activating factor acetylhydrolase activity in bovine seminal plasma.
    Parks JE, Hough SR.
    J Androl; 1993 Jul 09; 14(5):335-9. PubMed ID: 8288488
    [Abstract] [Full Text] [Related]

  • 33. The contribution of individual lipoproteins to the degradation of platelet-activating factor in human serum.
    Ostermann G, Kostner GM, Gries A, Malle E, Till U.
    Haemostasis; 1989 Jul 09; 19(3):160-8. PubMed ID: 2744632
    [Abstract] [Full Text] [Related]

  • 34. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions.
    Karabina SA, Liapikos TA, Grekas G, Goudevenos J, Tselepis AD.
    Biochim Biophys Acta; 1994 Jun 23; 1213(1):34-8. PubMed ID: 8011677
    [Abstract] [Full Text] [Related]

  • 35. Correlations between PAF-acether and tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids.
    Hilliquin P, Houbaba H, Aissa J, Benveniste J, Menkes CJ.
    Scand J Rheumatol; 1995 Jun 23; 24(3):169-73. PubMed ID: 7777830
    [Abstract] [Full Text] [Related]

  • 36. PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency.
    Surya II, Mommersteeg M, Erkelens DW, Akkerman JW.
    J Lipid Mediat; 1991 Jun 23; 3(1):27-38. PubMed ID: 1768838
    [Abstract] [Full Text] [Related]

  • 37. Long time incubation of monocytic U 937 cells with LDL increases specific paf-acether binding and the cellular acetylhydrolase activity.
    Korth R, Middeke M.
    Chem Phys Lipids; 1991 Oct 23; 59(3):207-13. PubMed ID: 1804564
    [Abstract] [Full Text] [Related]

  • 38. The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats.
    Wójcicka G, Zaręba M, Warpas A, Jamroz-Wiśniewska A, Rusek M, Czechowska G, Bełtowski J.
    Eur J Pharmacol; 2019 May 05; 850():180-189. PubMed ID: 30768981
    [Abstract] [Full Text] [Related]

  • 39. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension.
    Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Takamatsu M.
    Prostaglandins; 1989 Jun 05; 37(6):673-82. PubMed ID: 2772220
    [Abstract] [Full Text] [Related]

  • 40. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.
    MacPhee CH, Moores KE, Boyd HF, Dhanak D, Ife RJ, Leach CA, Leake DS, Milliner KJ, Patterson RA, Suckling KE, Tew DG, Hickey DM.
    Biochem J; 1999 Mar 01; 338 ( Pt 2)(Pt 2):479-87. PubMed ID: 10024526
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.